Latest Breaking News On - Crick avenue - Page 1 : comparemela.com

AstraZeneca : plans $1 5 billion manufacturing facility for antibody drug conjugates (ADCs) in Singapore - Form 6-K

a0072p FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or.

United statesUnited kingdomPascal soriotAdrian kempCommission file numberCompany on social media astrazenecaCompany secretarySecurities exchangeSingapore economic development boardInvestor relations teamForeign issuerSecurities exchange actFile numberCrick avenueRegulationst ruleCheong boon

AstraZeneca : SUPERNOVA Phase III trial of sipavibart long-acting antibody met primary endpoints in preventing COVID-19 in immunocompromised patient population - Form 6-K

a6269o FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or.

United kingdomUnited statesIskra reicGhady haidarAdrian kempMeerausw immunocompromiseHealth database studySecurities exchangeCompany on social media astrazenecaUniversity of pittsburgh medical centerLarge united states commercial insurance health planForum infect disInvestor relations teamCommission file numberCompany secretaryLancet regional health

AstraZeneca : Transaction by Person Discharging Managerial Responsibilities - Form 6-K

AstraZeneca : Transaction by Person Discharging Managerial Responsibilities - Form 6-K
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

United kingdomUnited statesPascal soriotAdrian kempEuropean union withdrawalCommission file numberCompany secretaryInvestor relations teamSecurities exchangeForeign issuerSecurities exchange actFile numberCrick avenueRegulationst rulePerson discharging managerial responsibilitiesChief executive officer

AstraZeneca : Calquence combination regimen demonstrated statistically significant and clinically meaningful improvement in progression-free survival in 1st-line mantle cell lymphoma in ECHO Phase III trial - Form 6-K

a9173m FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or.

United kingdomUnited statesAstrazeneca calquenceSusan galbraithAdrian kempLiud acalabrutinibMichael wangMd anderson cancer centerLymphoma research foundationCommission file numberInvestor relations teamGracell biotechnologies incMantle cell lymphoma program of excellenceNational organization for rare disordersCompany secretaryHealth database study

AstraZeneca : Imfinzi significantly improved overall survival and progression-free survival for patients with limited-stage small cell lung cancer in ADRIATIC Phase III trial - Form 6-K -April 05, 2024 at 06:26 am EDT

a4121j FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or.

United kingdomUnited statesNoord hollandSusan galbraithAstrazeneca imfinziAdrian kempDaiichi sankyoSuresh senanLung ambition allianceCompany secretaryCommission file numberInternational agency for research on cancerNational cancer instituteSecurities exchangeWorld health organizationLungevity foundation